Chemomab Therapeutics Ltd
CMMB1.890USD
-0.030-1.56%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
46.53MMarket Cap
LossP/E TTM
More Details of Chemomab Therapeutics Ltd Company
Chemomab Therapeutics Ltd (formerly known as Anchiano Therapeutics Ltd) is a Israel-based clinical-stage biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of fibrotic and inflammatory diseases with high unmet medical need among others. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.
Chemomab Therapeutics Ltd Info
Ticker SymbolCMMB
Company nameChemomab Therapeutics Ltd
IPO dateAug 14, 2012
CEOMor (Adi)
Number of employees16
Security typeDepository Receipt
Fiscal year-endAug 14
AddressKiryat Atidim, Building 7
CityTEL AVIV-YAFO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryIsrael
Postal code6158002
Phone972773310156
Websitehttps://www.chemomab.com/
Ticker SymbolCMMB
IPO dateAug 14, 2012
CEOMor (Adi)
Company Executives of Chemomab Therapeutics Ltd
Name
Name/Position
Position
Shareholding
Change
Ms. Sigal Fattal, CPA
Ms. Sigal Fattal, CPA
Chief Financial Officer
Chief Financial Officer
639.00
-82.96%
Dr. Nissim Darvish, M.D. Ph.D.
Dr. Nissim Darvish, M.D. Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
300.00
--
Mr. Neil Cohen
Mr. Neil Cohen
Independent Director
Independent Director
--
--
Dr. Alan Charles Moses, M.D.
Dr. Alan Charles Moses, M.D.
Independent Director
Independent Director
--
--
Dr. Claude Nicaise, M.D.
Dr. Claude Nicaise, M.D.
Independent Director
Independent Director
--
--
Ms. Irina Koffler
Ms. Irina Koffler
Investor Relations
Investor Relations
--
--
Dr. Adi Mor, Ph.D.
Dr. Adi Mor, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Jack Lawler
Mr. Jack Lawler
Chief Development Officer
Chief Development Officer
--
--
Dr. David M. Weiner, M.D.
Dr. David M. Weiner, M.D.
Interim Chief Medical Officer
Interim Chief Medical Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Sigal Fattal, CPA
Ms. Sigal Fattal, CPA
Chief Financial Officer
Chief Financial Officer
639.00
-82.96%
Dr. Nissim Darvish, M.D. Ph.D.
Dr. Nissim Darvish, M.D. Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
300.00
--
Mr. Neil Cohen
Mr. Neil Cohen
Independent Director
Independent Director
--
--
Dr. Alan Charles Moses, M.D.
Dr. Alan Charles Moses, M.D.
Independent Director
Independent Director
--
--
Dr. Claude Nicaise, M.D.
Dr. Claude Nicaise, M.D.
Independent Director
Independent Director
--
--
Ms. Irina Koffler
Ms. Irina Koffler
Investor Relations
Investor Relations
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Tue, Nov 18
Updated: Tue, Nov 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Otto (Erik)
6.86%
Apeiron Investment Group Ltd
4.60%
Rivendell Investments 2017-9 LLC
4.50%
Sphera Funds Management Ltd.
2.92%
Morgan Stanley & Co. LLC
1.46%
Other
79.66%
Shareholders
Shareholders
Proportion
Otto (Erik)
6.86%
Apeiron Investment Group Ltd
4.60%
Rivendell Investments 2017-9 LLC
4.50%
Sphera Funds Management Ltd.
2.92%
Morgan Stanley & Co. LLC
1.46%
Other
79.66%
Shareholder Types
Shareholders
Proportion
Individual Investor
9.55%
Family Office
4.60%
Corporation
4.50%
Hedge Fund
3.78%
Research Firm
1.91%
Investment Advisor/Hedge Fund
0.50%
Investment Advisor
0.16%
Other
75.00%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
30
390.31K
17.98%
--
2025Q3
30
390.31K
17.98%
-667.39K
2025Q2
30
1.06M
18.61%
+124.78K
2025Q1
31
932.92K
24.29%
-212.50K
2024Q4
32
1.04M
26.27%
-97.26K
2024Q3
29
1.14M
22.64%
+165.56K
2024Q2
28
668.24K
21.48%
+2.79K
2024Q1
32
666.14K
22.68%
-139.12K
2023Q4
33
705.36K
20.90%
+69.50K
2023Q3
33
635.85K
25.86%
-196.00
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Otto (Erik)
422.50K
8.17%
+133.75K
+46.32%
Aug 11, 2025
Apeiron Investment Group Ltd
283.00K
5.47%
+101.21K
+55.68%
Dec 31, 2024
Rivendell Investments 2017-9 LLC
277.13K
5.36%
--
--
Dec 31, 2024
Sphera Funds Management Ltd.
184.51K
3.57%
-40.59K
-18.03%
Jun 30, 2025
Morgan Stanley & Co. LLC
403.53K
7.8%
+374.24K
+1277.72%
Jun 30, 2025
Mor George (Adi)
79.27K
1.53%
--
--
Dec 31, 2024
Ikarian Capital LLC
53.26K
1.03%
--
--
Jun 30, 2025
George (Kobi)
50.06K
0.97%
-12.73K
-20.27%
Dec 31, 2024
Cohen (Neil Harris)
35.30K
0.68%
-2.50K
-6.61%
Dec 31, 2024
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Aug 08, 2025
Merger
4→1
Mar 16, 2021
Merger
16→1
Mar 16, 2021
Merger
16→1
Mar 16, 2021
Merger
16→1
Mar 16, 2021
Merger
16→1
Date
Type
Ratio
Aug 08, 2025
Merger
4→1
Mar 16, 2021
Merger
16→1
Mar 16, 2021
Merger
16→1
Mar 16, 2021
Merger
16→1
Mar 16, 2021
Merger
16→1
FAQs
Who are the top five shareholders of Chemomab Therapeutics Ltd?
The top five shareholders of Chemomab Therapeutics Ltd are:
Otto (Erik) holds 422.50K shares, accounting for 8.17% of the total shares.
Apeiron Investment Group Ltd holds 283.00K shares, accounting for 5.47% of the total shares.
Rivendell Investments 2017-9 LLC holds 277.13K shares, accounting for 5.36% of the total shares.
Sphera Funds Management Ltd. holds 184.51K shares, accounting for 3.57% of the total shares.
Morgan Stanley & Co. LLC holds 403.53K shares, accounting for 7.80% of the total shares.
Otto (Erik) holds 422.50K shares, accounting for 8.17% of the total shares.
Apeiron Investment Group Ltd holds 283.00K shares, accounting for 5.47% of the total shares.
Rivendell Investments 2017-9 LLC holds 277.13K shares, accounting for 5.36% of the total shares.
Sphera Funds Management Ltd. holds 184.51K shares, accounting for 3.57% of the total shares.
Morgan Stanley & Co. LLC holds 403.53K shares, accounting for 7.80% of the total shares.
What are the top three shareholder types of Chemomab Therapeutics Ltd?
The top three shareholder types of Chemomab Therapeutics Ltd are:
Otto (Erik)
Apeiron Investment Group Ltd
Rivendell Investments 2017-9 LLC
Otto (Erik)
Apeiron Investment Group Ltd
Rivendell Investments 2017-9 LLC
How many institutions hold shares of Chemomab Therapeutics Ltd (CMMB)?
As of 2025Q4, 30 institutions hold shares of Chemomab Therapeutics Ltd, with a combined market value of approximately 390.31K, accounting for 17.98% of the total shares. Compared to 2025Q3, institutional shareholding has increased by --.
What is the biggest source of revenue for Chemomab Therapeutics Ltd?
In --, the -- business generated the highest revenue for Chemomab Therapeutics Ltd, amounting to -- and accounting for --% of total revenue.
